ArticleFrontiers in bioengineering and biotechnology2022
Article in Frontiers in bioengineering and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- An age-related computational framework for predicting tibial fracture healing under walking rehabilitation: a comparison between younger and older adults.Medical & biological engineering & computing · 2026Article
- Leveraging polysaccharide-derived nanocarriers to open new horizons in oral vaccine activation.Materials today. Bio · 2025Review
- Beyond biologics: fungal polysaccharides as dual-function materials for nanomedicine.Nanomedicine (London, England) · 2025Review
- Plant-Derived Immunomodulatory Nanoadjuvants for Cancer Vaccines: Current Status and Future Opportunities.Vaccines · 2025Review
- The Role ofMolecules (Basel, Switzerland) · 2025Review
- Impact of Linggui Zhugan decoction on microwave ablation outcomes and recurrence in liver cancer.World journal of gastrointestinal oncology · 2025Article
- Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.Molecular cancer · 2025Review
- Traditional Chinese medicine as potential adjuvants for tumor vaccines: a review of types, mechanisms, and forms.Frontiers in immunology · 2025Review
- Review
- Antimicrobial and antibiofilm effects of cyclic dipeptide-rich fraction fromFrontiers in microbiology · 2024Article
- Integrating Chinese medicine into mainstream cancer therapies: a promising future.Frontiers in oncology · 2024Review
- The mechanical, optical, and thermal properties of graphene influencing its pre-clinical use in treating neurological diseases.Frontiers in neuroscience · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.